Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

- PMLiVE

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

- PMLiVE

Stelara outlook promising for psoriatic arthritis

Likely to be recommended alone and in combination with methotrexate

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Takeda’s Entyvio recommended by NICE for bowel disease

But must supply the drug at a discounted rate to the NHS

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

EU flag

EMA defends Humira redaction policy from transparency criticism

Regulator says spirit of trial transparency intact after its handling of AbbVie reports

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links